Abstracts tagged "anti-TNF therapy"

Abstract Number: 2331 • 2012 ACR/ARHP Annual Meeting
The Effects of Anti–Tumor Necrosis Factor Agents On the Expansion of T Helper-Type 17 Cells Driven by Lipopolysaccharide-Stimulated Monocytes
Gianluca Fossati¹, Louise Healy¹ and Andrew Nesbitt², ¹UCB Pharma, Slough, United Kingdom, ²UCB Pharma, SLough, United Kingdom
Background/Purpose: T helper-type 17 (Th17) cells are proinflammatory CD4+ cells characterized by the production of Interleukin-17 (IL-17).There is evidence that IL-17 and other cytokines which…
Abstract Number: 1560 • 2012 ACR/ARHP Annual Meeting
What Will Determine Adherence to Pharmaceutical Treatment for Rheumatoid Arthritis? A Systematic Review
Annelieke Pasma¹, Adriaan van 't Spijker², Jan van Busschbach³, Johanna M.W. Hazes⁴ and Jolanda J. Luime⁵, ¹Rheumatology, Erasmus MC University Medical Center, Rotterdam, Netherlands, ²Psychiatry, section Medical Psychology and Psychotherapy, Erasmus MC University Medical Center, Rotterdam, Netherlands, ³Medical Psychology and Psychotherapy, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁵Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: In the early stages of Rheumatoid Arthritis (RA), adherence to the prescribed treatment is important to prevent irreversible joint damage. However, medication adherence rates…
Abstract Number: 983 • 2012 ACR/ARHP Annual Meeting
Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 As a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis
Jing Cui¹ and International RA Consortium on Therapy (InteRACT)², ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy and Division of Genetics, Boston, MA
Background/Purpose: There are no biomarkers that predict response to anti-TNF therapy in rheumatoid arthritis (RA). Here, we conduct a genome-wide association study (GWAS) to identify…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.